Latest Intelligence on Pharmaceuticals and Healthcare in New Zealand

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Eli Lilly: further Zyprexa Adhera delays benefit Johnson & Johnson

Following the FDA's complete response letter for the drug, Eli Lilly has begun preparing a proposed risk evaluation mitigation strategy for Zyprexa Adhera. After the regulator's previous non-approval letter requesting more information regarding adverse effects in clinical trials, this further delay plays into the hands of Johnson & Johnson's direct competitor product paliperidone palmitate.

Published By Datamonitor
08 Jan 2009

« | 1 | » »|

No help is available.